Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • rojospan rojospan Jan 8, 2012 11:26 PM Flag

    Vertex Press Release; Comments re VX-770 Market

     

    Incivek 25000 patients x $ 49000 translates to 1.22 billions. TMC 435 can be a big headache. It can drop these numbers to Boceprevir sale number levels due to once daily dosage and JNJ co-development with Tibotec.

    Do you think Insurance companies will be willing to give 250 k/ yr for Kalydeco?
    Profit margins are going to be tight here. Drugs however works very good and response appear to be sustained.

    I wish VRTX can found a buyer like MRK or GSK.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • >>>Do you think Insurance companies will be willing to give 250 k/ yr for Kalydeco?

      Expect VRTX to price Kalydeco in the range of $100K/year for patients with insurance. Yes, Insurance companies will pay that amount if the clinical data is good and saves them money from other ongoing/needed clinical care. Being an orphan drug has benefits from insurance coverage as in the whole context the expense for insurance companies on Kalydeco will be marginal (very few patients qualify so low total cost for the Insurance Company).

 
VRTX
79.84-2.06(-2.52%)Jun 27 4:00 PMEDT